TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03916081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast Cream 0.05%
Description: Roflumilast 0.05% cream for topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast Cream 0.15%
Description: Roflumilast 0.15% cream for topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Inactive vehicle cream matched to roflumilast cream for topical application.
Study: NCT01240135

Intervention type: DEVICE
Group type: OTHER
Intervention: FID 114675A multi-purpose disinfecting solution (MPDS)
Description: Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: FID 114675A multi-purpose disinfecting solution (MPDS)
Description: Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: renu fresh Multi-Purpose Solution (MPS)
Description: Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: renu fresh Multi-Purpose Solution (MPS)
Description: Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A contact lenses (Acuvue Advance)
Description: A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A contact lenses (Acuvue Advance)
Description: A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
Study: NCT02168608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemia precondition
Description: Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: None remote ischemia precondition
Description: Placed an uninflated cuff on the right upper arm for 30 min.
Study: NCT02683863

Intervention type: DRUG
Group type: OTHER
Intervention: BG00012 (DMF) (Tecfidera®.)
Description: Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: BG00012 (DMF) (Tecfidera®.)
Description: Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: BG00012 (DMF) (Tecfidera®.)
Description: Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
Study: NCT05185908

Intervention type: PROCEDURE
Intervention: Measurement of the optic nerve sheath diameter by ultrasound-guidance.
Description: Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
Study: NCT02205580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion
Study: NCT01973205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 250 mg and Aspirin 250 mg
Description: 2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
Study: NCT03741634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-sectoral agricultural intervention
Description: Adult participants in the intervention arm receive a loan (\~$175) from a well-established Kenyan bank used to get a human-powered water pump, seeds, fertilizers and, pesticides, and education in financial management and sustainable farming practices.
Study: NCT03549702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone iodine 1% solution
Description: irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
Study: NCT03238911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside/ferric derisomaltose
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg).
Study: NCT00476151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream
Description: topical cream applied daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: inactive placebo cream applied two times daily
Study: NCT01498354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2-D high definition vision systems, transanal endoscopic operation (TEO)
Description: Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal endoscopic microsurgery (TEM)
Description: Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
Study: NCT00045201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study: NCT03238911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial.~Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
Study: NCT00382811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenoxodiol
Description: 400mg phenoxodiol three times daily in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=2 weekly in 28 day cycles
Study: NCT01494467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5024
Description: CD5024 1% Cream, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azelaic acid 15% Gel
Description: Topical Gel applied twice daily
Study: NCT02043652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
Study: NCT02855762

Intervention type: OTHER
Group type: OTHER
Intervention: High polyunsaturated fatty acid diet.
Description: The investigators hypothesize the diet will improve gut health and psychiatric clinical outcomes.
Study: NCT01308879

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contextualized Feedback Systems (CFS)tm
Description: After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contextualized Feedback Systems (CFS)tm
Description: After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
Study: NCT00728013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
Study: NCT06387940

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nEB Diet, followed for 36 hours
Description: nEB diet first, then LC25 and LCEB in random order with a 5 days washout between each diet
Study: NCT00382811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC=2 weekly in 28 day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: every 8 hours daily in 28 day cycles
Study: NCT06387940

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LC25 Diet, followed for 36 hours
Description: LC25 diet first, then nEB and LCEB in random order with a 5 days washout between each diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LCEB Diet, followed for 36 hours
Description: LCEB diet first, then LC25 and nEB in random order with a 5 days washout between each diet
Study: NCT00648466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan Succinate Tablets 100 mg
Description: 100mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex® Tablets 100 mg
Description: 100mg, single dose fasting
Study: NCT01543204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection
Study: NCT03403153

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SAHP
Description: Aim 1: To obtain and incorporate expert clinician and Veteran feedback on credibility, acceptability, and satisfaction with the intervention to ensure Veteran-friendly intervention manual, materials, and processes. Aim 1 will be accomplished through two rounds of expert panel review of treatment/MIA manual and two rounds of pilot testing of the treatment for Veteran Feedback in 16 female and 16 male Veterans.~Aim 2: To evaluate feasibility of study recruitment, retention, assessment procedures and proposed methods of the intervention. Preliminary examination of whether the intervention results in improvements to parenting behaviors, parenting satisfaction and overall family functioning.
Study: NCT04459156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber Inulin
Description: Commercially available inulin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber Inulin
Description: Commercially available inulin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber Inulin
Description: Commercially available inulin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Maltodextrin
Description: Commercially available maltodextrin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Maltodextrin
Description: Commercially available maltodextrin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
Study: NCT02683863

Intervention type: DRUG
Group type: OTHER
Intervention: BG00012 (DMF) (Tecfidera®.)
Description: Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
Study: NCT04459156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Maltodextrin
Description: Commercially available maltodextrin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
Study: NCT03214614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2451 multiple dose
Description: GLPG2451 oral suspension, multiple ascending doses, daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple dose
Description: Placebo, oral suspension, daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2451/GLPG2222 multiple dose
Description: GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
Study: NCT01124604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Hydrochloride
Description: Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
Study: NCT01784783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE Intervention
Description: If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.~Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVITE Intervention
Description: Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
Study: NCT00709371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zonisamide SR placebo/ bupropion SR placebo
Description: 2 placebo combination tablets twice daily for 16 weeks (maintenance period)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide SR placebo/ bupropion SR 360 mg/day
Description: 2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide SR 120 mg/day/ bupropion SR placebo
Description: 2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide SR 360 mg/day/ bupropion SR placebo
Description: 2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
Description: 2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day
Description: 2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Study: NCT04659746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MejoraCare
Description: mHealth solution to support remote monitoring of symptoms and patient empowerment through education.
Study: NCT03667352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Scalp Block
Description: Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Fentanyl
Description: Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
Study: NCT02502266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO
Study: NCT03214614

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined Placebo multiple dose
Description: Combined Placebo, oral suspension, daily for 14 days
Study: NCT03544047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).
Study: NCT04505215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Technique
Description: First, the painless application angle was determined for each patient. The lateral condyle of the humerus was fixed by the web range of the physiotherapist. The elbow joint was glided until the elbow joint and the hand tightening position were not able to cause pain.~The patients were asked to repeat the motion of the elbow joint and the ball squeezing motion given to their hands 10 times without pain. For pain control, the same procedure was performed with three sets, each containing 10 repetitions of the exercise. The interval between sets was 15 to 20 seconds, and the interval between repetitions within each set was 30 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Firstly, 5-7 sec opposite isometric muscle contraction was requested from the patient in the barrier by passively stretching by the physiotherapist until the barrier of the related muscle or dysfunctional joint. After a short rest period of 2-3 seconds, the physiotherapist continued to stretch passively until the second barrier. The application continued until the tension of the muscle or dysfunction of the joint disappeared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only Exercise (Control)
Description: Eccentric training for the extensor Carpi Radialis Brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercise for the EKRB muscle were given as home exercise program. The best stretching position for the EKRB tendon is provided when the elbow joint is in extension, forearm pronation, when the wrist is flexed with ulnar deviation (Mills maneuver). Each exercise was taught to patients in 10 repetitions and 10 seconds, and one day of the week, participants in the control group performed their exercises under the supervision of a physiotherapist.
Study: NCT04391439

Intervention type: DRUG
Intervention: Intravenous Methylprednisolone
Study: NCT00993278

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-Carbohydrate (Modified Atkins) Diet
Description: Low-Carbohydrate (Modified Atkins) Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-Fat (Heart Healthy) Diet
Description: Low-Fat (Heart Healthy) Diet
Study: NCT01351896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration